AU2001256440A1 - Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent - Google Patents

Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent

Info

Publication number
AU2001256440A1
AU2001256440A1 AU2001256440A AU5644001A AU2001256440A1 AU 2001256440 A1 AU2001256440 A1 AU 2001256440A1 AU 2001256440 A AU2001256440 A AU 2001256440A AU 5644001 A AU5644001 A AU 5644001A AU 2001256440 A1 AU2001256440 A1 AU 2001256440A1
Authority
AU
Australia
Prior art keywords
apoptosis
inducing agent
medicines
compound
tumoral pathologies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001256440A
Inventor
Arnaud Beurdeley-Thomas
Didier Decaudin
Guido Kroemer
Fariba Nemati
Marie-France Poupon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2001256440A1 publication Critical patent/AU2001256440A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention concerns the use of Ro5-4864, and compounds derived therefrom, for preparing medicines for treating tumoral pathologies. The invention also concerns said compounds combined with an apoptosis-inducing agent, as combination products for simultaneous, separate or prolonged use, in cancer therapy.
AU2001256440A 2000-04-28 2001-04-27 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent Abandoned AU2001256440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0005438 2000-04-28
FR0005438A FR2808197A1 (en) 2000-04-28 2000-04-28 USE OF RO5-4864 COMPOUND AND DERIVED COMPOUNDS FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF TUMOR DISEASES
PCT/FR2001/001322 WO2001082969A2 (en) 2000-04-28 2001-04-27 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent

Publications (1)

Publication Number Publication Date
AU2001256440A1 true AU2001256440A1 (en) 2001-11-12

Family

ID=8849699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001256440A Abandoned AU2001256440A1 (en) 2000-04-28 2001-04-27 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent

Country Status (10)

Country Link
US (1) US20030166598A1 (en)
EP (1) EP1276504B1 (en)
JP (1) JP2003531868A (en)
AT (1) ATE287730T1 (en)
AU (1) AU2001256440A1 (en)
CA (1) CA2407338A1 (en)
DE (1) DE60108622T2 (en)
ES (1) ES2234835T3 (en)
FR (1) FR2808197A1 (en)
WO (1) WO2001082969A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101917B2 (en) 2003-04-14 2006-09-05 Hoffmann-La Roche Inc. Mitochrondrial permeability transition pore affinity labels and modulators
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58167514A (en) * 1982-03-26 1983-10-03 Itaru Yamamoto Immunological regulating agent
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
WO1999056736A2 (en) * 1998-05-06 1999-11-11 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Apoptosis-inducing compounds
WO1999058117A1 (en) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Use of compounds for reducing apoptosis
FR2779963A1 (en) * 1998-06-22 1999-12-24 Centre Nat Rech Scient New composition useful for treat cancer, comprises compound with affinity for mitochondrial benzodiazepine receptors and agent to induce apoptosis

Also Published As

Publication number Publication date
EP1276504B1 (en) 2005-01-26
WO2001082969A3 (en) 2002-04-18
WO2001082969A2 (en) 2001-11-08
FR2808197A1 (en) 2001-11-02
JP2003531868A (en) 2003-10-28
DE60108622D1 (en) 2005-03-03
ATE287730T1 (en) 2005-02-15
EP1276504A2 (en) 2003-01-22
US20030166598A1 (en) 2003-09-04
DE60108622T2 (en) 2005-06-23
ES2234835T3 (en) 2005-07-01
CA2407338A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
WO2003080582A3 (en) Fredericamycin derivatives
AU2001282399A1 (en) Resorcinol derivatives
TW200508214A (en) Novel compounds
SI1187632T1 (en) TREATMENT WITH ANTI-ErbB2 ANTIBODIES
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
TW200600091A (en) Sulfonylethyl phosphorodiamidates
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU2158601A (en) Antiviral agent for use in treatment of cancer
IL146125A0 (en) Novel quinones as disease therapies
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
MY121523A (en) Resorcinol derivatives
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
BR0008307A (en) Use of an enterobacterium ompa protein or one of its fragments, and pharmaceutical composition
TW200504051A (en) Novel acridine derivatives and their use as medicaments
MXPA04000272A (en) Substituted 4-aminocyclohexanol derivatives.
YU3400A (en) New salts with beneficial organoleptic properties
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
AU4558201A (en) Taxane anticancer agents
WO2000030587A3 (en) NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
WO2003014128A3 (en) Tumour inhibiting cerium compounds
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
AU6290398A (en) Inclusion complexes in aqueous solution